Cisen Pharmaceutical Co., Ltd. (SHA:603367)
China · Delayed Price · Currency is CNY 15.66
+0.52 (3.43%)
Apr 29, 2026, 3:00 PM CST
Cisen Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,427 | 3,972 | 4,451 | 4,049 | 3,773 |
Other Revenue | 17.56 | 10.02 | 11.14 | 16.83 | 9.62 |
| 3,445 | 3,982 | 4,462 | 4,066 | 3,783 | |
Revenue Growth (YoY) | -13.48% | -10.77% | 9.74% | 7.50% | 2.95% |
Cost of Revenue | 1,734 | 1,813 | 1,913 | 1,827 | 1,728 |
Gross Profit | 1,711 | 2,168 | 2,550 | 2,239 | 2,055 |
Selling, General & Admin | 1,113 | 1,367 | 1,600 | 1,544 | 1,455 |
Research & Development | 285.78 | 342.64 | 374.88 | 335.17 | 334.35 |
Other Operating Expenses | 30.42 | 18.02 | 20.97 | 55.37 | 50.31 |
Operating Expenses | 1,440 | 1,724 | 1,999 | 1,948 | 1,841 |
Operating Income | 270.96 | 444.59 | 550.79 | 291.2 | 214.24 |
Interest Expense | -1.34 | -6.95 | -6.59 | -4.29 | -6.1 |
Interest & Investment Income | 156.08 | 101.87 | 85.7 | 53 | 90.18 |
Currency Exchange Gain (Loss) | -0.79 | 0.54 | 0.55 | -0.32 | -0.62 |
Other Non Operating Income (Expenses) | -0.3 | 3.65 | -1.27 | -0.17 | 5.21 |
EBT Excluding Unusual Items | 424.61 | 543.71 | 629.19 | 339.41 | 302.91 |
Gain (Loss) on Sale of Investments | 39.68 | 10.53 | -10.37 | -3.12 | -6.09 |
Gain (Loss) on Sale of Assets | -0.71 | -0.14 | 0.59 | 0.97 | 0.27 |
Asset Writedown | -0.66 | -0.63 | -27.79 | 0.01 | -0.04 |
Other Unusual Items | 33.27 | 22.3 | 4.24 | 28.92 | 39.09 |
Pretax Income | 496.19 | 575.77 | 595.86 | 366.19 | 336.13 |
Income Tax Expense | 70.58 | 60.83 | 70.43 | 13.92 | 2.23 |
Earnings From Continuing Operations | 425.62 | 514.94 | 525.43 | 352.27 | 333.9 |
Minority Interest in Earnings | -4.37 | -6.03 | -4.09 | -2.31 | 0.24 |
Net Income | 421.25 | 508.91 | 521.34 | 349.96 | 334.15 |
Net Income to Common | 421.25 | 508.91 | 521.34 | 349.96 | 334.15 |
Net Income Growth | -17.22% | -2.38% | 48.97% | 4.73% | -23.85% |
Shares Outstanding (Basic) | 453 | 454 | 453 | 454 | 452 |
Shares Outstanding (Diluted) | 453 | 454 | 453 | 454 | 452 |
Shares Change (YoY) | -0.31% | 0.23% | -0.25% | 0.65% | -0.18% |
EPS (Basic) | 0.93 | 1.12 | 1.15 | 0.77 | 0.74 |
EPS (Diluted) | 0.93 | 1.12 | 1.15 | 0.77 | 0.74 |
EPS Growth | -16.96% | -2.61% | 49.35% | 4.05% | -23.71% |
Free Cash Flow | 401.61 | 469.04 | 433.53 | 223.15 | 182.58 |
Free Cash Flow Per Share | 0.89 | 1.03 | 0.96 | 0.49 | 0.40 |
Dividend Per Share | 0.348 | 0.440 | 0.436 | 0.335 | 0.300 |
Dividend Growth | -20.91% | 0.92% | 30.15% | 11.67% | 17.19% |
Gross Margin | 49.66% | 54.46% | 57.14% | 55.06% | 54.32% |
Operating Margin | 7.87% | 11.17% | 12.34% | 7.16% | 5.66% |
Profit Margin | 12.23% | 12.78% | 11.68% | 8.61% | 8.83% |
Free Cash Flow Margin | 11.66% | 11.78% | 9.71% | 5.49% | 4.83% |
EBITDA | 466.28 | 665.34 | 781.54 | 519.77 | 432.08 |
EBITDA Margin | 13.54% | 16.71% | 17.51% | 12.78% | 11.42% |
D&A For EBITDA | 195.32 | 220.74 | 230.75 | 228.57 | 217.84 |
EBIT | 270.96 | 444.59 | 550.79 | 291.2 | 214.24 |
EBIT Margin | 7.87% | 11.17% | 12.34% | 7.16% | 5.66% |
Effective Tax Rate | 14.22% | 10.56% | 11.82% | 3.80% | 0.66% |
Revenue as Reported | 3,445 | 3,982 | 4,462 | 4,066 | 3,783 |
Advertising Expenses | 19.91 | 1.47 | 0.82 | 0.2 | 0.51 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.